Medivir Overview

  • Year Founded
  • 1988

Year Founded

  • Status
  • Public

  • Employees
  • 10

Employees

  • Stock Symbol
  • MVIR

Stock Symbol

  • Investments
  • 5

  • Share Price
  • $0.12
  • (As of Friday Closing)

Medivir General Information

Description

Medivir AB develops therapies targeting diseases with high unmet medical need. The group's drug candidates focus on indications where current treatment options are limited or non-existent, offering the potential to deliver meaningful improvements for patients. Its two programs are fostrox, designed to target liver cancer cells while minimizing side effects selectively, and MIV-711, aimed at treating Osteogenesis Imperfecta (Brittle bone disease) and Legg-Calve-Perthes disease (Perthes disease). It has developed two pharmaceutical products: Xerclear, used for treating labial herpes (cold sores), and Olysio, which have reached the market. It also has four out-licensed projects, Xerclear, MIV-701, MBLI/MET-X, and remetinostat. Geographic revenue is generated from Europe and other regions.

Contact Information

Website
www.medivir.com
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • Lunastigen 5
  • 2nd Floor, Box 1086
  • 141 22 Huddinge
  • Sweden
+46 08-546
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Stock Exchange
STO
Vertical(s)
Corporate Office
  • Lunastigen 5
  • 2nd Floor, Box 1086
  • 141 22 Huddinge
  • Sweden
+46 08-546

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Medivir Stock Performance

As of 13-Nov-2026, Medivir’s stock price is $0.12. Its current market cap is $72M with 624M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.12 $0.12 $0.04 - $0.31 $72M 624M 1.83M -$0.03

Medivir Financials Summary

As of 30-Sep-2026, Medivir has a trailing 12-month revenue of $905K.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 76,897 17,419 20,539 23,685
Revenue 905 866 329 718
EBITDA (6,151) (6,058) (11,335) (8,062)
Net Income (9,440) (9,608) (11,660) (8,404)
Total Assets 32,643 21,430 15,642 28,809
Total Debt 0 912 1,003 1,354
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Medivir Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Medivir‘s full profile, request access.

Request a free trial

Medivir Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Medivir AB develops therapies targeting diseases with high unmet medical need. The group's drug candidates focus on indi
Drug Discovery
Huddinge, Sweden
10 As of 2026

Cerdanyola, Spain
 

North Chesterfield, VA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Medivir Competitors (9)

One of Medivir’s 9 competitors is Ability Pharma, a Private Equity-Backed company based in Cerdanyola, Spain.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Ability Pharma Private Equity-Backed Cerdanyola, Spain
Indivior Corporate Backed or Acquired North Chesterfield, VA
Bristol-Myers Squibb Corporation Princeton, NJ
BioInvent International Formerly VC-backed Lund, Sweden
Ultragenyx Pharmaceutical Formerly VC-backed Novato, CA
You’re viewing 5 of 9 competitors. Get the full list »

Medivir Patents

Medivir Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026185278-A1 N-[1-6-(ethynyl-3-oxo-hexahydro-furo[3,2-b]pyrrole-4-carbonyl)-3-methyl-butyl]-4-[5-fluoro-2-(4- methyl-piperazin-1-yl)thiazol-4-yl]-benzamide for use in the treatment of osteogenesis imperfecta Pending 05-Mar-2025
AU-2025233872-A1 Treatment of bone loss Pending 06-Mar-2024
EP-4613273-A1 Treatment of bone loss Inactive 06-Mar-2024
WO-2025186343-A1 Treatment of bone loss Pending 06-Mar-2024
WO-2025186343-A8 Treatment of bone loss Pending 06-Mar-2024 A61K31/496
To view Medivir’s complete patent history, request access »

Medivir Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Medivir Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Medivir‘s full profile, request access.

Request a free trial

Medivir Investments & Acquisitions (5)

Medivir’s most recent deal was a Corporate Asset Purchase with Tetralogic Pharmaceuticals (Portfolio of Clinical Stage Oncology Programs) for . The deal was made on 29-Dec-2016.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Tetralogic Pharmaceuticals (Portfolio of Clinical Stage Oncology Programs) 29-Dec-2016 Corporate Asset Purchase Other Healthcare Technology Systems
Novadex Pharmaceuticals (Preclinical Research Stage Assets in Umea, Sweden) 05-Sep-2012 Corporate Asset Purchase Buildings and Property
BioPhausia 11-Jun-2011 Merger/Acquisition Distributors (Healthcare)
Presidio Pharmaceuticals 09-Jul-2009 Early Stage VC Drug Discovery
Mimetrix 27-Mar-2000 Merger/Acquisition Drug Discovery
To view Medivir’s complete investments and acquisitions history, request access »

Medivir ESG

Risk Overview

Risk Rating

Updated November, 30, 2024

38.02 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 14,271

Rank

Percentile

Pharmaceuticals

Industry

of 908

Rank

Percentile

Biotechnology

Subindustry

of 434

Rank

Percentile

To view Medivir’s complete esg history, request access »

Medivir Exits (2)

Medivir’s most recent exit was on 11-Jun-2011 from BioPhausia. The exit was categorized as .

Company Name Exit Date Exit Type Exit Size Status Buyers
BioPhausia 11-Jun-2011 Completed
Presidio Pharmaceuticals 09-Jul-2009 Early Stage VC Completed
  • 8 buyers
To view Medivir’s complete exits history, request access »

Medivir Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Medivir Personal Huddinge, Sweden 2000

Medivir FAQs

  • When was Medivir founded?

    Medivir was founded in 1988.

  • Where is Medivir headquartered?

    Medivir is headquartered in Huddinge, Sweden.

  • What is the size of Medivir?

    Medivir has 10 total employees.

  • What industry is Medivir in?

    Medivir’s primary industry is Drug Discovery.

  • Is Medivir a private or public company?

    Medivir is a Public company.

  • What is Medivir’s stock symbol?

    The ticker symbol for Medivir is MVIR.

  • What is the current stock price of Medivir?

    As of 13-Nov-2026 the stock price of Medivir is $0.12.

  • What is the current market cap of Medivir?

    The current market capitalization of Medivir is $72M.

  • What is Medivir’s current revenue?

    The trailing twelve month revenue for Medivir is $905K.

  • Who are Medivir’s competitors?

    Ability Pharma, Indivior, Bristol-Myers Squibb, BioInvent International, and Ultragenyx Pharmaceutical are some of the 9 competitors of Medivir.

  • What is Medivir’s annual earnings per share (EPS)?

    Medivir’s EPS for 12 months was -$0.03.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process